U.S. News & World Report - For those with the deadliest form of skin cancer, there's a new drug on the horizon--one that shows promise in slowing tumor growth and helping patients live longer. In a trial of more than 600 patients with metastatic melanoma, those taking Swiss drugmaker Roche's RG7204, an experimental pill that attacks a gene mutation found in about half of melanoma patients, lived longer than those given dacarbazine, the standard treatment. Their disease also advanced more slowly, Roche announced Wednesday. ...
More...
More...